Key regions: France, Europe, United Kingdom, Brazil, India
The Oncology Drugs market in Gabon has been growing steadily over the past few years.
Customer preferences: Gabon's population has been increasing, and with it, the number of cancer cases. This has led to an increased demand for oncology drugs in the country. Patients in Gabon are looking for effective and affordable treatments that can help them fight cancer.
Trends in the market: One of the major trends in the Oncology Drugs market in Gabon is the increasing availability of generic drugs. Generic drugs are cheaper than their branded counterparts, making them more accessible to patients. This has led to an increase in the number of patients seeking treatment for cancer.Another trend in the market is the increasing use of immunotherapy. Immunotherapy is a type of cancer treatment that uses the body's immune system to fight cancer. It has been shown to be effective in treating certain types of cancer, and is becoming more widely available in Gabon.
Local special circumstances: One of the challenges in the Oncology Drugs market in Gabon is the lack of infrastructure. Many hospitals and clinics do not have the necessary equipment to diagnose and treat cancer. This has led to a reliance on foreign hospitals and clinics for treatment, which can be expensive and inaccessible for many patients.
Underlying macroeconomic factors: Gabon's economy has been growing steadily over the past few years, which has led to an increase in healthcare spending. The government has been investing in healthcare infrastructure, which has led to an increase in the availability of oncology drugs in the country. Additionally, Gabon is a member of the Central African Economic and Monetary Community (CEMAC), which has led to increased trade and investment in the country. This has made it easier for pharmaceutical companies to do business in Gabon, which has led to an increase in the availability of oncology drugs.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
